Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004299 | PO / MO |
The patient with cellulitis was receiving antibiotics Ke and Vivotif at the same time; Case reference number US-BN-2025-001105 is a spontaneous case initially received from a other health professional via Communication (reference number: USBAV25-1473) on 20-Jun-2025 and concerns an adult male patient. The patient's medical history and concomitant medication details were not provided. The patient's current condition includes cellulitis. *As reported, the patient took Keflex one gram for seven days at the frequency of three times per day.* On *16-Jun-2025*, the patient took first dose of Vivotif (batch number: *3004299) at dose of one capsule, orally for indication typhoid fever prophylaxis*. At the same time the patient was also receiving antibiotics of *Keflex (batch number: unknown) at unknown dose route or site of administration, three times a day for seven days*, for indication cellulitis (explicitly coded as 'contraindicated product administered'). *On 18-Jun-2025, two days after first dose, the patient took second dose of Vivotif (batch number: *3004299) at dose of one capsule, orally. * *On 20-Jun-2025, two days after second dose, the patient took third dose of Vivotif (batch number: *3004299) at dose of one capsule orally.* *On 22-Jun-2025, two days after third dose, the patient took fourth dose of Vivotif (batch number: *3004299) at dose of one capsule orally. * At the time of the *follow-up* report, it was unknown if the patient experienced any adverse event due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a other health professional on 18-Jul-2025: New information included patient gender, age, Vivotif dosing details and treatment medication were added.; Reporter's Comments: An adult male patient took first dose of Vivotif, at an unknown dose, or route of administration for an indication of typhoid fever prophylaxis. Reportedly, at the same time the patient was also receiving antibiotics of Keflex for cellulitis which is considered as contraindicated product administered. Contraindicated product administered is considered listed per company conventions. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's current condition includes cellulitis. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: An adult male patient took first dose of Vivotif, at an unknown dose, or route of administration for an indication of typhoid fever prophylaxis. Reportedly, at the same time the patient was also receiving antibiotics of Keflex for cellulitis which is considered as contraindicated product administered. Contraindicated product administered is considered listed per company conventions. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's current condition includes cellulitis. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Medical History/Concurrent Conditions: Cellulitis; Comments: None.
KEFLEX [CEFALEXIN]